All In Biotech

Drug Trial Radar · NCT06588179

SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt

Phase Ib/II Clinical Study of SHR-1501 Combined With SHR-2005 in the Treatment of Patients With High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

58

Planned (sponsor's estimate)

Start

Oct 1, 2024

Primary completion

Oct 1, 2027

Study completion Oct 1, 2027

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center, single-arm, phase Ib/II study, aimed at assessing the safety and efficacy of SHR-1501 in combination with SHR-2005 as treatment for patients with high-risk non-muscle invasive bladder cancer (HR NMIBC) which is not completely resectable by transurethral resection of bladder tumor (TURBt).

Conditions

  • NMIBC

Interventions

  • SHR-1501+SHR-2005Drug

    SHR-1501, instillation;SHR-2005, instillation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I : Incidence of dose limiting toxicities (DLTs)Time frame: From Day 1 to Day 21
  2. Phase I : RP2D(Recommended Phase 2 dose)Time frame: From Day 1 to 90 days after last dose
  3. Phase I : Incidence and severity of adverse events (AEs)Time frame: From Day 1 to 90 days after last dose
  4. Phase II : CR rate at 3 monthsTime frame: Approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.